Objective: To evaluate the association between lymphovascular invasion (LVI) and different clinicopathologic features of invasive breast cancer.
Introduction
Lymphovascular invasion (LVI) is an essential step for breast cancer progression and metastasis. LVI has been suggested as a prognostic marker for long term survival in lymph node negative tumors. Rakha, et al. studied the role of LVI as a prognostic marker for breast cancer, (3) concluding that LVI predicts worse outcome and higher metastatic potential.
(3)
This finding was consistent among different subgroup analyses based on established clinicopathologic features of breast cancer. In a follow-up multiinstitutional study, Rakha et al. reported that LVI is an important outcome predictor among metaplastic breast cancer patients.
However, Ejlertsen, et al. reported a low potential of LVI as a high-risk predictor.
In their study, 16172 patients were investigated, and LVI was found to be associated with overall survival only in the high-risk group .
(6)
Additionally, most of the data from the literature on the prognostic value of LVI were derived from lymph node negative patients.
(1-
4)
Furthermore, most of the studies focused on the role of LVI in predicting disease survival and metastatic potential. The association For department of: between LVI and different clinicopathologic features has been rarely investigated. The aim of this study is to evaluate the association between LVI and different clinicopathologic features of invasive breast cancer.
Methods
Two hundred and ninety eight patients with a diagnosis of invasive breast cancer, who had undergone surgery in King Hussein Medical Center (KHMC) between 2007 and 2014, were included in this study. The study was approved by the local ethics committee of the Royal Medical Services. All patients had full clinicopathologic evaluation at the pathology department of KHMC. Pathologic studies were conducted on paraffin embedded sections derived from tumor samples obtained during surgical management of the patients. The criteria for lymphovascular invasion were defined as the presence of tumor emboli in peritumoral lymphovascular spaces, identified microscopically with or without the aid of endothelial markers. The status of estrogen receptor (ER) and progesterone receptor (PR) were determined by immunohistochemistry, positivity defined as the presence of staining of 1% or more of tumor cells with strong intensity. Only cases with score 3 on immunohistochemistry were included in our definition of Her2 positive cases and equivocal cases were excluded. A rabbit monoclonal primary antibody clones (Ventana) were used to assess hormonal and Her-2 status. Data were extracted from the patients' records and pathology reports, and slides were re-assessed by one of the authors (a senior pathologist). In some cases, further immunostaining were performed as needed to confirm the presence of LVI or hormonal/Her-2 status. The pathologic assessment and the ER, PR, and Her-2 status were interpreted according to the recommendations by the College of American Pathologists (CAP). 
Statistical analysis:
All statistical analyses were performed using statistical package for social sciences (SPSS) version 22.00 (SPSS Inc., Chicago, IL). Chi square test was used to assess significance between LVI and other clinicopathologic parameters evaluated on nominal and ordinal scale. Differences in age and size between groups with patients with present and absent lymphovascular invasion were compared using student t-test. A p value of less than 0.05 was considered significant.
Results
The average age of the cohort under investigation was 51.2 years (51.2±12.97). One hundred and eighty two patients (61.1%) had invasive ductal carcinoma, whereas 36 patients (12.1%) had invasive lobular carcinoma. The rest of the patients (26.8%) had other types. The average size of excised tumors was 3.86 cm (3.86±2.2). The majority of patients were estrogen and progesterone (PR) positive (72.1 and 68.1% respectively). In contrast, 78.2% of patients were Her2 negative. Clinicopathologic characteristics are outlined in Table I . Patients with positive LVI had significantly larger tumor size (4.2 vs. 3.4 cm, p=0.001; Figure 1A ), and they also had higher number of involved lymph nodes (5.6 vs. 2.7, p<0.000; Figure 1B ). However, there was no significant change in the mean age of patients with present or absent lymphovascular invasion (50.9 vs. 49.4, p=0.771; Figure 1C (Figure 2A; χ2=1.672, p=0.196) . In contrast to ER status, patients with progesterone negative tumors were more likely to have LVI ( Figure 2B; 
Discussion
Our data demonstrate a possible role of lymphovascular invasion (LVI) as a prognostic marker in locally invasive breast cancer patients. LVI was associated with larger tumors and more lymph node involvement. Additionally, it was associated with both progesterone negative and Her2 positive status. The incidence of LVI was not affected by ER status. The role of LVI as a prognostic marker has been well established in patients with lymph node negative breast cancer.
(2-4)
Additionally, its importance across different subtypes of breast cancer has been well established.
(3)
Despite the well-established role as a prognostic factor, the association of LVI with different clinicopathological breast cancer features has been rarely addressed. In this study, an attempt to characterize the association between different breast cancer features and LVI was made. This characterization will provide insight on the interaction between LVI and other clinicopathological characteristics of breast cancer. It will also provide better understanding of the biology and molecular control of LVI in breast cancer.
Our data demonstrate an association between LVI and the extent of lymph node involvement. Patients with LVI were more likely to have lymph node involvement and higher number of involved lymph nodes. These findings are consistent with previous reports on the association between LVI and lymph node involvement. Ugras et al,.reported low incidence of lymph node involvement in patients with negative LVI (10) . Additionally, Rakha, et al., reported that about 80% of patients with lymph node negative breast cancer had negative LVI.
Similarly, our data on the association between tumor size and grade are in complete conformity with these reports. Hormone receptor and Her2 status are well established prognostic factors in breast cancer patients ,
(1,7-11) and they have an essential role in selecting treatment modality.
(11)
The prognostic value of LVI in patients with different hormone receptor and Her2 status has been well established. Interestingly, the association between LVI and these markers has not been investigated thoroughly. Rakha et al. reported that LVI is an independent prognostic factor in Her2 negative tumors. However, the occurrence of LVI was similar in patients with Her2 positive and negative tumors. In contrast, our data indicates a higher occurrence of LVI in Her2 positive patients. Marinho et al. reported a negative association between ER, PR status and LVI.
(12) Similarly in our study, patients with PR negative tumors were more likely to have LVI. On the other hand, LVI did not differ between patients with ER positive tumors and ER negative tumors. These findings indicated a critical role of PR in controlling LVI and supports previous reports on the negative association between ER and LVI. Additionally, they provide an insight on the possible mechanisms of LVI. However, other variables (such as the antibody clones and cold ischemia time) also need to be investigated. Perineural invasion is considered a sign of aggressive behavior potential in most tumor systems.
(13)
However, its significance in invasive breast carcinoma is not yet well established and is currently only reported for completeness of pathologic reports.
(14)
Interestingly, a more recent publication concluded that perineural invasion were identified as parameters negatively associated with patient survival, based on both univariate and multivariate analyses. In our study, patients with negative LVI were more likely to have negative perineural invasion (p=0.0001). Previous studies (14) showed that perineural invasion is seen more in patients with higher tumor stage, higher tumor grade and LVI.
Conclusions
Lymphovascular invasion varies by tumor size and number of lymph nodes involved but not by patient age. The incidence of LVI was related to tumor grade and is differentially affected by hormone receptor status: it appears to be more likely in patients with progesterone negative and in patients who are Her2 positive. Patients with negative LVI were more likely to have negative perineural invasion. A study of LVI in a multivariate analysis in relation to clinical outcome is needed to assess effect of LVI status on prognosis.
